Literature DB >> 12149225

V(H) mutation status, CD38 expression level, genomic aberrations, and survival in chronic lymphocytic leukemia.

Alexander Kröber1, Till Seiler, Axel Benner, Lars Bullinger, Elsbeth Brückle, Peter Lichter, Hartmut Döhner, Stephan Stilgenbauer.   

Abstract

In chronic lymphocytic leukemia (CLL), biologic risk factors such as immunoglobulin variable heavy chain gene (V(H)) mutation status, CD38 expression level, and genomic aberrations have recently been identified, but the relative prognostic impact of the individual parameters is unknown. In the current study, we analyzed V(H) mutation status by polymerase chain reaction and sequencing (n = 300), genomic aberrations by fluorescence in situ hybridization (+3q, 6q-, +8q, 11q-, +12q, 13q-, t(14q), 17p-) (n = 300), and CD38 expression by triple-color FACS (CD5, CD19, CD38) (n = 157) in a unicentric CLL cohort. The prognostic influence of V(H) mutation rate and CD38 expression level was tested by maximally selected log-rank statistics. A corrected P value (P(cor)) for a cutoff level allowing the best separation of 2 subgroups with different survival probabilities was identified at 97% V(H) homology (95% confidence interval [CI], 96%-98% homology, P(cor) <.001) and at 7% CD38 expression (95% CI, 20%-71% expression, P(cor) =.02). In univariate analyses, unmutated V(H) genes and high CD38 expression levels predicted for shorter survival times. The overall incidence of genomic aberrations was similar in the V(H) unmutated and V(H) mutated subgroups. High-risk genomic aberrations such as 17p- and 11q- occurred almost exclusively in the V(H) unmutated subgroup, whereas favorable aberrations such as 13q- and 13q- as single abnormalities were overrepresented in the V(H) mutated subgroup. In multivariate analysis, unmutated V(H), 17p deletion, 11q deletion, age, WBC, and LDH were identified as independent prognostic factors, indicating a complementary role of V(H) mutation status and genomic aberrations to predict outcome in CLL.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12149225

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  144 in total

1.  Automated array-based genomic profiling in chronic lymphocytic leukemia: development of a clinical tool and discovery of recurrent genomic alterations.

Authors:  Carsten Schwaenen; Michelle Nessling; Swen Wessendorf; Tatjana Salvi; Gunnar Wrobel; Bernhard Radlwimmer; Hans A Kestler; Christian Haslinger; Stephan Stilgenbauer; Hartmut Döhner; Martin Bentz; Peter Lichter
Journal:  Proc Natl Acad Sci U S A       Date:  2004-01-16       Impact factor: 11.205

2.  Molecular detection of the G(-248)A BAX promoter nucleotide change in B cell chronic lymphocytic leukaemia.

Authors:  O Moshynska; K Sankaran; A Saxena
Journal:  Mol Pathol       Date:  2003-08

Review 3.  Challenges in the frontline treatment of patients with chronic lymphocytic leukemia.

Authors:  Nicole Lamanna
Journal:  Curr Hematol Malig Rep       Date:  2010-01       Impact factor: 3.952

4.  Prognostic factors identified three risk groups in the LRF CLL4 trial, independent of treatment allocation.

Authors:  David Oscier; Rachel Wade; Zadie Davis; Alison Morilla; Giles Best; Sue Richards; Monica Else; Estella Matutes; Daniel Catovsky
Journal:  Haematologica       Date:  2010-05-29       Impact factor: 9.941

5.  White blood cell count at diagnosis and immunoglobulin variable region gene mutations are independent predictors of treatment-free survival in young patients with stage A chronic lymphocytic leukemia.

Authors:  Ilaria Del Giudice; Francesca Romana Mauro; Maria Stefania De Propris; Simona Santangelo; Marilisa Marinelli; Nadia Peragine; Valeria Di Maio; Mauro Nanni; Rita Barzotti; Francesca Mancini; Daniele Armiento; Francesca Paoloni; Anna Guarini; Robin Foà
Journal:  Haematologica       Date:  2010-12-29       Impact factor: 9.941

6.  Immunoglobulin mutational status detected through single-round amplification of partial V(H) region represents a good prognostic marker for clinical outcome in chronic lymphocytic leukemia.

Authors:  Roberto Marasca; Rossana Maffei; Monica Morselli; Patrizia Zucchini; Ilaria Castelli; Silvia Martinelli; Marcella Fontana; Sara Ravanetti; Monica Curotti; Giovanna Leonardi; Katia Cagossi; Giovanni Partesotti; Giuseppe Torelli
Journal:  J Mol Diagn       Date:  2005-11       Impact factor: 5.568

7.  Lipoprotein Lipase as a Prognostic Marker in Chronic Lymphocytic Leukemia.

Authors:  Zoltán Mátrai; Hajnalka Andrikovics; Anikó Szilvási; András Bors; András Kozma; Emma Ádám; Gabriella Halm; Éva Karászi; Attila Tordai; Tamás Masszi
Journal:  Pathol Oncol Res       Date:  2016-10-18       Impact factor: 3.201

8.  Dic(17;18)(p11.2;p11.2) is a recurring abnormality in chronic lymphocytic leukaemia associated with aggressive disease.

Authors:  Jennifer A Woyach; Nyla A Heerema; John Zhao; Andrew McFaddin; Amy Stark; Thomas S Lin; Leslie A Andritsos; Kristie A Blum; Joseph M Flynn; Jeffrey A Jones; John C Byrd
Journal:  Br J Haematol       Date:  2009-12-16       Impact factor: 6.998

Review 9.  From pathogenesis to treatment of chronic lymphocytic leukaemia.

Authors:  Thorsten Zenz; Daniel Mertens; Ralf Küppers; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Nat Rev Cancer       Date:  2009-12-03       Impact factor: 60.716

10.  Aggressive chronic lymphocytic leukemia with elevated genomic complexity is associated with multiple gene defects in the response to DNA double-strand breaks.

Authors:  Peter Ouillette; Samuel Fossum; Brian Parkin; Li Ding; Paula Bockenstedt; Ammar Al-Zoubi; Kerby Shedden; Sami N Malek
Journal:  Clin Cancer Res       Date:  2010-01-19       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.